By Chris Wack
VYNE Therapeutics said Monday that it saw positive data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.
The Phase 1b trial is a 16-week open-label trial assessing the safety, tolerability and pharmacokinetics of once-daily topical VYN201 in 29 patients across three dose cohorts, 0.5%, 1.0% and 2.0% strengths.
Exploratory efficacy of VYN201 was also evaluated, including VYN201’s ability to arrest the progression of skin depigmentation and support skin repigmentation in patients with active disease, through changes in the facial vitiligo area scoring index.
The company saw new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis.
VYNE Therapeutics also said it has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses.
In the PIPE, VYNE is selling 10.7 million shares of its stock at $2.245 a share and pre-funded warrants to buy up to 28.6 million shares at $2.2449 per pre-funded warrant.
Write to Chris Wack at [email protected]
Read the full article here